|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3850 - 0.3850|
|52 Week Range||0.3000 - 4.2000|
|Beta (3Y Monthly)||1.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
THOUSAND OAKS, CA / ACCESSWIRE / August 9, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK:CBDG) developer of CBD based oral health products, today announced - that the Company is now offering a powerful new tool to help with gum disease diagnosis and treatment. A simple rinse test from OralDNA® Labs identifies individual genetic susceptibility to periodontal disease. All salivary diagnostic tests can be ordered from the same simple oral rinse collection, disease-causing bacteria and helps personalize doctor prescribed treatment.
THOUSAND OAKS, CA / ACCESSWIRE / June 12, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK: CBDG) today announced that its parent company has been granted patent protection for the South African Patent Application No. 2017/01966 regarding the parent company's Methods of Producing Antibody- Rich Cannabis and Honeysuckle Plants. South African Republic's Patent Office has scheduled publication of this international patent for June 26, 2019. This invention relates generally to the production of antibody-rich cannabis and honeysuckle plants.
THOUSAND OAKS, CA / ACCESSWIRE / March 6, 2019 / THC Farmaceuticals, Inc. (OTC PINK: CBDG) today announced that it completed the acquisition of a 50% interest in a corporation that owns 78 acres of land in Southern California. THC Farmaceuticals, Inc. also became an authorized retailer for products from CW California, Inc., a wholesale distributor of premium hemp supplements and preferred distributor of the World's Most Trusted Hemp ExtractTM product line ''Charlotte's WebTM'', as well as Elixinol, Myriams Hope, Topikal CBD, and Canniatric. The company's facility is located in southern California, where we provide easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products.
THOUSAND OAKS, CA / ACCESSWIRE / October 17, 2018 / THC Farmaceuticals, Inc. (OTC PINK: CBDG) announces that it has completed the acquisition of a majority ownership in CBDual Biotechnology Corp., a start-up biotech company focused on the development of proprietary products containing CBD (cannabidiol) and/or THC (Tetrahydrocannabinol). Per the agreement, THC Farmaceuticals has committed $250,000 USD in funding and has issued 1,500,000 common shares to CBDual Biotechnology, completing the first phase of the acquisition. The funding, which has begun, and is paid in tranches, will enable CBDual Biotechnology to further implement its operations.